Related Experiment Video
Updated: May 9, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
A surview of recent patents on anti-infective therapy for Clostridium difficile
Germine S Soliman1, Bechoi Saleib, Stephen J Scholand
1St. Mary's Hospital Department of Internal Medicine, 56 Franklin Street, Waterbury, CT 06706, USA. germine.soliman@gmail.com
Abstract:
Clostridium difficile has become the most common infectious cause of healthcare-associated diarrhea, with serious morbidity, prolonged hospitalization and even death. Treatment of the disease utilizing today's therapies does not guarantee a successful outcome. In the past decade, many new ideas and inventions have surfaced exploring different treatment strategies of Clostridium difficile associated diarrhea (CDAD). These treatments include antitoxins, novel antimicrobials, immunoglobulins and large inert synthetic compounds. In this paper, we survey of a number of representative patents issued from 2000 to the present targeting treatment of this difficult and dreaded disease.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Antimicrobial Effectiveness
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Transduction
